Mahmoud A. Khaimi
Research Subjects
Mahmoud A. Khaimi has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Ben J. Harvey
Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, USA
2 shared publicationsEvan J. Allan
Dean McGee Eye Institute †University of Oklahoma College of Medicine ‡Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
2 shared publicationsJoshua M. Jones
Disclosure: The authors declare no conflict of interest
2 shared publicationsKai Ding
Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
2 shared publicationsAnnah Baykal
Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, USA
1 shared publicationChristian Leal
Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, USA
1 shared publication
Latest Publications
- 26 May 2026
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 264 (11) , 3673-3687
Canaloplasty via an ab-interno approach in primary open-angle glaucoma: Results from a large case series
To evaluate the effectiveness and safety of ab-interno canaloplasty using the iTrack microcatheter in patients with primary open-angle glaucoma (POAG). This retrospective, single-center case series included eyes with POAG treated with iTrack ab-interno canaloplasty (Nova Eye Medical, USA), performed either as a standalone procedure or combined with phacoemulsification, with a minimum follow-up of 12 months. Primary outcomes were changes in IOP and number of glaucoma medications. Secondary outcomes included visual acuity (VA), visual field (VF) mean deviation (MD), complications, need for additional glaucoma surgery, and surgical success (as defined by American Academy of Ophthalmology [AAO] criteria). Subgroup analyses were conducted based on disease severity, baseline IOP (≤ 18 mmHg vs. > 18 mmHg), and preoperative medication use (0-4). Both standalone (n = 167) and combined (n = 364) procedures achieved significant reductions in IOP and medication use (p < 0.001). At the last follow-up (mean: 20.4 ± 7.7 months), mean IOP was reduced by 3.29 ± 6.0 mmHg in the combined group (from 17.5 ± 5.8 to 14.2 ± 3.8 mmHg) and by 4.50 ± 6.1 mmHg in the standalone group (from 20.2 ± 6.0 to 15.7 ± 4.3 mmHg), with the standalone group showing a significantly greater absolute IOP reduction (p = 0.025). Medication burden was reduced by 1.05 ± 1.06 medications in the combined group and by 0.84 ± 1.15 in the standalone group (p = 0.032). Subgroup analyses confirmed significant IOP and/or medication reductions across all strata, with greater relative benefits in eyes with uncontrolled baseline IOP (> 18 mmHg). Surgical success was 64% in combined and 47% in standalone procedures; success was 75% and 46% in eyes with uncontrolled and controlled baseline IOP. Intraoperative complications were infrequent (1.6%), and 13.1% of eyes required additional glaucoma surgery during follow-up. Ab-interno canaloplasty using the iTrack microcatheter, whether as a standalone procedure or combined with phacoemulsification, resulted in sustained reductions in IOP and medication use, with a low rate of complications. These outcomes were consistent across varying levels of disease severity and baseline IOP, with the most pronounced benefits observed in eyes with elevated preoperative IOP.
- 26 May 2026
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 264 (11) , 3673-3687
Canaloplasty via an ab-interno approach in primary open-angle glaucoma: Results from a large case series
To evaluate the effectiveness and safety of ab-interno canaloplasty using the iTrack microcatheter in patients with primary open-angle glaucoma (POAG). This retrospective, single-center case series included eyes with POAG treated with iTrack ab-interno canaloplasty (Nova Eye Medical, USA), performed either as a standalone procedure or combined with phacoemulsification, with a minimum follow-up of 12 months. Primary outcomes were changes in IOP and number of glaucoma medications. Secondary outcomes included visual acuity (VA), visual field (VF) mean deviation (MD), complications, need for additional glaucoma surgery, and surgical success (as defined by American Academy of Ophthalmology [AAO] criteria). Subgroup analyses were conducted based on disease severity, baseline IOP (≤ 18 mmHg vs. > 18 mmHg), and preoperative medication use (0-4). Both standalone (n = 167) and combined (n = 364) procedures achieved significant reductions in IOP and medication use (p < 0.001). At the last follow-up (mean: 20.4 ± 7.7 months), mean IOP was reduced by 3.29 ± 6.0 mmHg in the combined group (from 17.5 ± 5.8 to 14.2 ± 3.8 mmHg) and by 4.50 ± 6.1 mmHg in the standalone group (from 20.2 ± 6.0 to 15.7 ± 4.3 mmHg), with the standalone group showing a significantly greater absolute IOP reduction (p = 0.025). Medication burden was reduced by 1.05 ± 1.06 medications in the combined group and by 0.84 ± 1.15 in the standalone group (p = 0.032). Subgroup analyses confirmed significant IOP and/or medication reductions across all strata, with greater relative benefits in eyes with uncontrolled baseline IOP (> 18 mmHg). Surgical success was 64% in combined and 47% in standalone procedures; success was 75% and 46% in eyes with uncontrolled and controlled baseline IOP. Intraoperative complications were infrequent (1.6%), and 13.1% of eyes required additional glaucoma surgery during follow-up. Ab-interno canaloplasty using the iTrack microcatheter, whether as a standalone procedure or combined with phacoemulsification, resulted in sustained reductions in IOP and medication use, with a low rate of complications. These outcomes were consistent across varying levels of disease severity and baseline IOP, with the most pronounced benefits observed in eyes with elevated preoperative IOP.
- Open Access
- 4 October 2024
- Published by Springer Nature in International Ophthalmology
- Vol. 44 (1) , 1-11
Canaloplasty via an ab-interno surgical technique in patients with primary angle closure glaucoma
Purpose To investigate the clinical outcomes of canaloplasty performed with the iTrack microcatheter (Nova Eye Medical, Fremont, USA) as a standalone procedure and in combination with phacoemulsification in patients with primary angle-closure glaucoma (PACG). Methods A single-center, retrospective case series of eyes undergoing canaloplasty via an ab-interno technique with a diagnosis of PACG based on gonioscopy findings (Shaffer grading). Patients were excluded if they had previously undergone a glaucoma procedure other than Laser Peripheral Iridotomy (LPI). Eyes were grouped by glaucoma severity based on mean deviation preoperative values. Outcome measures included intraocular pressure (IOP) and number of glaucoma medications. Results Sixty eyes (9 canaloplasty-standalone, pseudophakic, and 51 canaloplasty + phaco) were eligible. The mean baseline IOP was 21.9 ± 7.3 mmHg and number of glaucoma medications was 1.95 ± 1.4. At the latest follow-up (mean 26 ± 9.2 months), they were reduced to 14.6 ± 3.7 mmHg (p < 0.001) and 0.96 ± 1.2 (p < 0.001). IOP reduction was statistically significant when canaloplasty was performed as a standalone procedure (baseline 22.78 ± 6.72 vs 17.00 ± 3.42 at the latest follow-up) or combined with phacoemulsification (21.75 ± 7.43 vs 14.21 ± 3.66) or if canaloplasty was performed in mild (20.8 ± 4.93 vs 15.5 ± 3.63), moderate (21.9 ± 8.58 vs 13.9 ± 3.90) or severe (23.5 ± 11.3 vs 12.4 ± 3.20) glaucoma eyes, with no difference between the groups postoperatively. Medication reduction was significant when canaloplasty was performed in combination with phacoemulsification and in mild glaucoma eyes. No serious intraoperative or postoperative complications were reported. Conclusion Canaloplasty via an ab-interno surgical technique, performed as standalone or combined with phacoemulsification, is a safe and clinically effective treatment in primary angle closure glaucoma patients up to 2 years.
- 4 October 2024
- Published by Springer Nature in International Ophthalmology
- Vol. 44 (1) , 1-11
Open AccessCanaloplasty via an ab-interno surgical technique in patients with primary angle closure glaucoma
Purpose To investigate the clinical outcomes of canaloplasty performed with the iTrack microcatheter (Nova Eye Medical, Fremont, USA) as a standalone procedure and in combination with phacoemulsification in patients with primary angle-closure glaucoma (PACG). Methods A single-center, retrospective case series of eyes undergoing canaloplasty via an ab-interno technique with a diagnosis of PACG based on gonioscopy findings (Shaffer grading). Patients were excluded if they had previously undergone a glaucoma procedure other than Laser Peripheral Iridotomy (LPI). Eyes were grouped by glaucoma severity based on mean deviation preoperative values. Outcome measures included intraocular pressure (IOP) and number of glaucoma medications. Results Sixty eyes (9 canaloplasty-standalone, pseudophakic, and 51 canaloplasty + phaco) were eligible. The mean baseline IOP was 21.9 ± 7.3 mmHg and number of glaucoma medications was 1.95 ± 1.4. At the latest follow-up (mean 26 ± 9.2 months), they were reduced to 14.6 ± 3.7 mmHg (p < 0.001) and 0.96 ± 1.2 (p < 0.001). IOP reduction was statistically significant when canaloplasty was performed as a standalone procedure (baseline 22.78 ± 6.72 vs 17.00 ± 3.42 at the latest follow-up) or combined with phacoemulsification (21.75 ± 7.43 vs 14.21 ± 3.66) or if canaloplasty was performed in mild (20.8 ± 4.93 vs 15.5 ± 3.63), moderate (21.9 ± 8.58 vs 13.9 ± 3.90) or severe (23.5 ± 11.3 vs 12.4 ± 3.20) glaucoma eyes, with no difference between the groups postoperatively. Medication reduction was significant when canaloplasty was performed in combination with phacoemulsification and in mild glaucoma eyes. No serious intraoperative or postoperative complications were reported. Conclusion Canaloplasty via an ab-interno surgical technique, performed as standalone or combined with phacoemulsification, is a safe and clinically effective treatment in primary angle closure glaucoma patients up to 2 years.
- Open Access
- 1 January 2024
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 18, 173-183
Consistency in Standalone Canaloplasty Outcomes Using the iTrack Microcatheter
Purpose: To study the consistency in outcomes of standalone canaloplasty performed via an ab-interno surgical technique in reducing intraocular pressure (IOP) and number of medications in uncontrolled open-angle glaucoma (OAG) eyes over a 12-month period. Methods: This retrospective multicenter case series included patients who underwent standalone canaloplasty via an ab-interno surgical technique using the iTrack microcatheter (Nova Eye, Inc., Fremont, USA) and had preoperative uncontrolled OAG (IOP≥ 18mmHg) along with no previous glaucoma surgery. The iTrack microcatheter is used to circumnavigate 360° and viscodilate Schlemm’s canal. Consistency of IOP and medications reduction on an eye-by-eye basis were evaluated to understand the outcomes in each single eye. Results: Sixty-four eyes of 60 patients (age 71.5± 13.4 years) were included. Six eyes (9%) that underwent additional glaucoma surgery were considered a failure and were subsequently excluded from analysis. At 12 months, IOP was reduced in 57 of the 58 (89%) remaining eyes; one eye had the same IOP with a reduced number of medications. Of the 57/58 eyes with a reduced IOP: 44 eyes (69%) required fewer medications; 12 eyes (19%) required the same number of medications. Of these 58 eyes, 78% of eyes had a ≥ 20% reduction in IOP compared to baseline; 69% eyes had a postoperative IOP ≤ 15 mmHg, and 86% eyes ≤ 18 mmHg at 12 months. Forty percent of the eyes were medication-free at 12 months compared to none at baseline. Conclusion: Canaloplasty performed via an ab-interno surgical technique as a standalone procedure consistently reduced IOP and glaucoma medications in almost all eyes.
- 1 January 2024
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 18, 173-183
Open AccessConsistency in Standalone Canaloplasty Outcomes Using the iTrack Microcatheter
Purpose: To study the consistency in outcomes of standalone canaloplasty performed via an ab-interno surgical technique in reducing intraocular pressure (IOP) and number of medications in uncontrolled open-angle glaucoma (OAG) eyes over a 12-month period. Methods: This retrospective multicenter case series included patients who underwent standalone canaloplasty via an ab-interno surgical technique using the iTrack microcatheter (Nova Eye, Inc., Fremont, USA) and had preoperative uncontrolled OAG (IOP≥ 18mmHg) along with no previous glaucoma surgery. The iTrack microcatheter is used to circumnavigate 360° and viscodilate Schlemm’s canal. Consistency of IOP and medications reduction on an eye-by-eye basis were evaluated to understand the outcomes in each single eye. Results: Sixty-four eyes of 60 patients (age 71.5± 13.4 years) were included. Six eyes (9%) that underwent additional glaucoma surgery were considered a failure and were subsequently excluded from analysis. At 12 months, IOP was reduced in 57 of the 58 (89%) remaining eyes; one eye had the same IOP with a reduced number of medications. Of the 57/58 eyes with a reduced IOP: 44 eyes (69%) required fewer medications; 12 eyes (19%) required the same number of medications. Of these 58 eyes, 78% of eyes had a ≥ 20% reduction in IOP compared to baseline; 69% eyes had a postoperative IOP ≤ 15 mmHg, and 86% eyes ≤ 18 mmHg at 12 months. Forty percent of the eyes were medication-free at 12 months compared to none at baseline. Conclusion: Canaloplasty performed via an ab-interno surgical technique as a standalone procedure consistently reduced IOP and glaucoma medications in almost all eyes.
- 4 March 2022
- Published by Wolters Kluwer Health in Cornea
- Vol. 42 (1) , 52-59
Surgical Management of Intraocular Pressure With Ab Interno Canaloplasty in Postkeratoplasty Patients: 12-Month Results
Purpose: The purpose of this study was to report clinical outcomes of ab interno canaloplasty (ABiC) with the iTrack microcatheter (Nova Eye Medical, Fremont, CA) for surgical management of intraocular pressure (IOP) in postkeratoplasty patients. Methods: This study was a single-center retrospective case series of postkeratoplasty eyes undergoing ABiC. Efficacy was evaluated based on graft survivability and mean reduction in IOP at 12 months postoperatively. Secondary end points consisted of visual acuity outcomes, number of topical hypotensive medications, and rate of complications. Results: ABiC was successfully performed in 17 eyes after keratoplasty (8 penetrating keratoplasty, 6 DSAEK, 2 penetrating keratoplasty + DSAEK, and 1 DMEK) with elevated IOP refractory to topical hypotensive medications. The baseline mean IOP was 26.2 ± 8.4 mm Hg and reduced significantly to 15.0 ± 4.21 mm Hg at 6 months and 13.0 ± 2.99 mm Hg at 12 months (P < 0.005). The best-corrected visual acuity improved from 0.61 ± 0.55 logMAR at baseline to 0.47 ± 0.59 and 0.49 ± 0.64 at 6 and 12 months, respectively, following ABiC (not statistically significant: P = 0.6769). The baseline mean number of topical hypotensive medications was 3.7 ± 1.8 and reduced to 2.7 ± 1.4 and 2.9 ± 1.3 at 6 and 12 months, respectively (P = 0.096). One patient developed a hyphema which required anterior chamber washout. One patient required additional glaucoma surgery 19 months after ABiC. No patients experienced graft failure. Conclusions: ABiC is a clinically safe and effective treatment that can be performed in postkeratoplasty patients to reduce IOP for at least 1 year without any significant complications.
- 4 March 2022
- Published by Wolters Kluwer Health in Cornea
- Vol. 42 (1) , 52-59
Surgical Management of Intraocular Pressure With Ab Interno Canaloplasty in Postkeratoplasty Patients: 12-Month Results
Purpose: The purpose of this study was to report clinical outcomes of ab interno canaloplasty (ABiC) with the iTrack microcatheter (Nova Eye Medical, Fremont, CA) for surgical management of intraocular pressure (IOP) in postkeratoplasty patients. Methods: This study was a single-center retrospective case series of postkeratoplasty eyes undergoing ABiC. Efficacy was evaluated based on graft survivability and mean reduction in IOP at 12 months postoperatively. Secondary end points consisted of visual acuity outcomes, number of topical hypotensive medications, and rate of complications. Results: ABiC was successfully performed in 17 eyes after keratoplasty (8 penetrating keratoplasty, 6 DSAEK, 2 penetrating keratoplasty + DSAEK, and 1 DMEK) with elevated IOP refractory to topical hypotensive medications. The baseline mean IOP was 26.2 ± 8.4 mm Hg and reduced significantly to 15.0 ± 4.21 mm Hg at 6 months and 13.0 ± 2.99 mm Hg at 12 months (P < 0.005). The best-corrected visual acuity improved from 0.61 ± 0.55 logMAR at baseline to 0.47 ± 0.59 and 0.49 ± 0.64 at 6 and 12 months, respectively, following ABiC (not statistically significant: P = 0.6769). The baseline mean number of topical hypotensive medications was 3.7 ± 1.8 and reduced to 2.7 ± 1.4 and 2.9 ± 1.3 at 6 and 12 months, respectively (P = 0.096). One patient developed a hyphema which required anterior chamber washout. One patient required additional glaucoma surgery 19 months after ABiC. No patients experienced graft failure. Conclusions: ABiC is a clinically safe and effective treatment that can be performed in postkeratoplasty patients to reduce IOP for at least 1 year without any significant complications.
- Open Access
- 1 January 2021
- Published by SAGE Publications in Therapeutic Advances in Ophthalmology
- Vol. 13
Long-term medication reduction in controlled glaucoma with iTrack ab-interno canaloplasty as a standalone procedure and combined with cataract surgery
To evaluate the long-term effectiveness of iTrack (Nova Eye Medical, Fremont, USA) ab-interno canaloplasty performed as a standalone procedure, or combined with cataract surgery, in reducing antiglaucoma medication dependence and maintaining intraocular pressure within target range in patients with controlled primary open-angle glaucoma. This is a retrospective, single-center, case series study of patients who underwent iTrack ab-interno canaloplasty as a standalone procedure (n = 34) or in combination with cataract surgery (n = 11). Eyes with controlled mild or moderate glaucoma (intraocular pressure ⩽17 mmHg) were included; those with prior glaucoma surgeries were excluded. The primary outcome was the mean reduction in glaucoma medication and the secondary outcome was the maintenance of controlled intraocular pressure postoperatively. A total of 35 patients (45 eyes) with a mean age of 73 ± 9.7 years were included in the study. For all eyes, a significant decrease (61%) in the mean number of medications was seen at 36 months (1.89 ± 0.93 versus 0.60 ± 0.82; p < 0.001), with 56% (14/25) of eyes medication free. No significant difference was observed in the reduction of medication use whether iTrack was performed with or without cataract surgery at 12 and 36 months. Mean baseline intraocular pressure of 14.42 ± 2.2 mmHg for all eyes was maintained at the 12-, 24-, and 36-month follow-up visits (14.6 ± 3.65, 15.06 ± 2.26, and 14.19 ± 2.91, respectively), with no significant difference between the two groups (p = 0.08). The iTrack ab-interno canaloplasty significantly reduced medication dependency and maintained intraocular pressure within target range in patients with controlled mild or moderate primary open-angle glaucoma, while showing a good safety profile, both as a standalone procedure or in combination with cataract surgery.
- 1 January 2021
- Published by SAGE Publications in Therapeutic Advances in Ophthalmology
- Vol. 13
Open AccessLong-term medication reduction in controlled glaucoma with iTrack ab-interno canaloplasty as a standalone procedure and combined with cataract surgery
To evaluate the long-term effectiveness of iTrack (Nova Eye Medical, Fremont, USA) ab-interno canaloplasty performed as a standalone procedure, or combined with cataract surgery, in reducing antiglaucoma medication dependence and maintaining intraocular pressure within target range in patients with controlled primary open-angle glaucoma. This is a retrospective, single-center, case series study of patients who underwent iTrack ab-interno canaloplasty as a standalone procedure (n = 34) or in combination with cataract surgery (n = 11). Eyes with controlled mild or moderate glaucoma (intraocular pressure ⩽17 mmHg) were included; those with prior glaucoma surgeries were excluded. The primary outcome was the mean reduction in glaucoma medication and the secondary outcome was the maintenance of controlled intraocular pressure postoperatively. A total of 35 patients (45 eyes) with a mean age of 73 ± 9.7 years were included in the study. For all eyes, a significant decrease (61%) in the mean number of medications was seen at 36 months (1.89 ± 0.93 versus 0.60 ± 0.82; p < 0.001), with 56% (14/25) of eyes medication free. No significant difference was observed in the reduction of medication use whether iTrack was performed with or without cataract surgery at 12 and 36 months. Mean baseline intraocular pressure of 14.42 ± 2.2 mmHg for all eyes was maintained at the 12-, 24-, and 36-month follow-up visits (14.6 ± 3.65, 15.06 ± 2.26, and 14.19 ± 2.91, respectively), with no significant difference between the two groups (p = 0.08). The iTrack ab-interno canaloplasty significantly reduced medication dependency and maintained intraocular pressure within target range in patients with controlled mild or moderate primary open-angle glaucoma, while showing a good safety profile, both as a standalone procedure or in combination with cataract surgery.
- 21 December 2020
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 30 (3) , 235-241
Evaluation of Spin in the Abstracts of Systematic Reviews and Meta-analyses of Treatments for Glaucoma
Purpose: Spin—the misrepresentation of the study’s actual findings—carries the ability to distort a reader’s perception of a treatments’ full benefits and risks. Recent studies have suggested that spin is common in abstracts of randomized controlled trials and systematic reviews focused on treatments for a variety of medical disorders. Therefore, our primary objective was to evaluate the prevalence of spin in the abstracts of systematic reviews and meta-analyses related to glaucoma treatments. We further assessed whether specific study characteristics were associated with spin, including the methodological quality of a study. Patients and Methods: We used a cross-sectional study design searching MEDLINE and Embase databases all for systematic reviews and meta-analyses focused on glaucoma treatments. Each abstract was assessed for the 9 most severe—severity determined by the likelihood of distorting a reader’s perception—types of spin that occur in systematic review abstracts. The screening and data extraction was performed in a duplicate, masked fashion. The methodological quality of each review was assessed using the A MeaSurement Tool to Assess Systematic Reviews (AMSTAR-2) instrument. To evaluate relationships between spin, AMSTAR-2 appraisals, and other study characteristics, we used unadjusted odds ratios and the Fisher exact test. Results: Only 3 of the 102 abstracts contained spin, with spin type 5 being the most prevalent. No abstracts contained spin types 1, 2, 3, 4, 6, or 8, and no association was found between the presence of spin in an abstract and any particular study characteristic. Using the AMSTAR-2 quality appraisal instrument, 35 (34.3%) of the studies received a methodological quality rating as high, 42 (41.2%) as moderate, 11 (10.8%) as low, and 14 (13.7%) as critically low. Conclusions: We found that spin is present in only a small proportion of systematic reviews and meta-analyses covering the treatment of glaucoma. In comparison to studies in other fields of medicine, ophthalmology appears to be a leader in publishing systematic reviews and meta-analyses with low rates of spin occurring in the
- 21 December 2020
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 30 (3) , 235-241
Evaluation of Spin in the Abstracts of Systematic Reviews and Meta-analyses of Treatments for Glaucoma
Purpose: Spin—the misrepresentation of the study’s actual findings—carries the ability to distort a reader’s perception of a treatments’ full benefits and risks. Recent studies have suggested that spin is common in abstracts of randomized controlled trials and systematic reviews focused on treatments for a variety of medical disorders. Therefore, our primary objective was to evaluate the prevalence of spin in the abstracts of systematic reviews and meta-analyses related to glaucoma treatments. We further assessed whether specific study characteristics were associated with spin, including the methodological quality of a study. Patients and Methods: We used a cross-sectional study design searching MEDLINE and Embase databases all for systematic reviews and meta-analyses focused on glaucoma treatments. Each abstract was assessed for the 9 most severe—severity determined by the likelihood of distorting a reader’s perception—types of spin that occur in systematic review abstracts. The screening and data extraction was performed in a duplicate, masked fashion. The methodological quality of each review was assessed using the A MeaSurement Tool to Assess Systematic Reviews (AMSTAR-2) instrument. To evaluate relationships between spin, AMSTAR-2 appraisals, and other study characteristics, we used unadjusted odds ratios and the Fisher exact test. Results: Only 3 of the 102 abstracts contained spin, with spin type 5 being the most prevalent. No abstracts contained spin types 1, 2, 3, 4, 6, or 8, and no association was found between the presence of spin in an abstract and any particular study characteristic. Using the AMSTAR-2 quality appraisal instrument, 35 (34.3%) of the studies received a methodological quality rating as high, 42 (41.2%) as moderate, 11 (10.8%) as low, and 14 (13.7%) as critically low. Conclusions: We found that spin is present in only a small proportion of systematic reviews and meta-analyses covering the treatment of glaucoma. In comparison to studies in other fields of medicine, ophthalmology appears to be a leader in publishing systematic reviews and meta-analyses with low rates of spin occurring in the
- Open Access
- 1 February 2018
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 12, 319-329
A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
Background: While loteprednol etabonate (LE) suspension 0.5% is approved for the treatment of postoperative ocular inflammation, there have been no reported studies of its use in glaucoma patients undergoing canaloplasty. Methods: This was a retrospective medical chart review conducted at a single US center. Data were collected on patients with glaucoma who underwent canaloplasty with or without cataract surgery, and were prescribed LE suspension 0.5% postoperatively. Outcomes evaluated included postsurgical inflammation (anterior chamber [AC] cells and flare), intraocular pressure (IOP), number of IOP-lowering medications, and postsurgical complications. Results: Data were collected on 204 patients (262 eyes) with a mean (SD) age of 71.6 (11.3) years. The most frequent LE dosing regimens at day 1, week 1, and month 1 postsurgery were QID (92.3%; 241/261), TID (52.6%; 133/253), and QD (65.5%; 78/119), respectively. Inflammation (AC flare and cells), mostly mild, was noted in 33.2% (86/259) of eyes on postoperative day 1 and 8.6% (21/244) of eyes at month 1. Mean IOP and mean number of IOP-lowering medications were significantly reduced from baseline (PConclusion: These real-world data suggest that canaloplasty with or without cataract surgery managed postoperatively with LE suspension 0.5% is effective and safe in the glaucoma patient.
- 1 February 2018
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 12, 319-329
Open AccessA retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
Background: While loteprednol etabonate (LE) suspension 0.5% is approved for the treatment of postoperative ocular inflammation, there have been no reported studies of its use in glaucoma patients undergoing canaloplasty. Methods: This was a retrospective medical chart review conducted at a single US center. Data were collected on patients with glaucoma who underwent canaloplasty with or without cataract surgery, and were prescribed LE suspension 0.5% postoperatively. Outcomes evaluated included postsurgical inflammation (anterior chamber [AC] cells and flare), intraocular pressure (IOP), number of IOP-lowering medications, and postsurgical complications. Results: Data were collected on 204 patients (262 eyes) with a mean (SD) age of 71.6 (11.3) years. The most frequent LE dosing regimens at day 1, week 1, and month 1 postsurgery were QID (92.3%; 241/261), TID (52.6%; 133/253), and QD (65.5%; 78/119), respectively. Inflammation (AC flare and cells), mostly mild, was noted in 33.2% (86/259) of eyes on postoperative day 1 and 8.6% (21/244) of eyes at month 1. Mean IOP and mean number of IOP-lowering medications were significantly reduced from baseline (PConclusion: These real-world data suggest that canaloplasty with or without cataract surgery managed postoperatively with LE suspension 0.5% is effective and safe in the glaucoma patient.
- Open Access
- 29 September 2017
- Published by Wiley in Journal of Ophthalmology
- Vol. 2017, 1-7
An Analysis of 3-Year Outcomes Following Canaloplasty for the Treatment of Open-Angle Glaucoma
Purpose. To report 3-year results investigating the safety and efficacy of canaloplasty for open-angle glaucoma. Setting. University of Oklahoma, Dean McGee Eye Institute, Oklahoma, United States of America. Design. Nonrandomized single-center retrospective chart review. Methods. Adult open-angle glaucoma eyes underwent canaloplasty or combined cataract-canaloplasty surgery. A tensioning suture was placed into Schlemm’s canal in all eyes. Primary endpoints included the mean IOP and mean number of glaucoma medications at each follow-up visit. Secondary endpoints included visual acuity and surgical/postsurgical complications. Results. The study cohort included 277 eyes (mean age, 72.8 years). Overall, the mean baseline IOP of 19.7 mmHg was reduced to 14.3 mmHg,14.0 mmHg, and 15.2 mmHg at 1, 2, and 3 years, respectively (). The average medicine use was reduced from 2.1 preoperatively to 0.4 at 12 months, and 0.5 and 0.6 at two and three years, respectively (). The frequency of surgical and postsurgical complications was low with no serious adverse events recorded. Conclusion. Canaloplasty was safe and effective in achieving long-term IOP reductions and reduced dependence on antiglaucoma medications.- 29 September 2017
- Published by Wiley in Journal of Ophthalmology
- Vol. 2017, 1-7
Open AccessAn Analysis of 3-Year Outcomes Following Canaloplasty for the Treatment of Open-Angle Glaucoma
Purpose. To report 3-year results investigating the safety and efficacy of canaloplasty for open-angle glaucoma. Setting. University of Oklahoma, Dean McGee Eye Institute, Oklahoma, United States of America. Design. Nonrandomized single-center retrospective chart review. Methods. Adult open-angle glaucoma eyes underwent canaloplasty or combined cataract-canaloplasty surgery. A tensioning suture was placed into Schlemm’s canal in all eyes. Primary endpoints included the mean IOP and mean number of glaucoma medications at each follow-up visit. Secondary endpoints included visual acuity and surgical/postsurgical complications. Results. The study cohort included 277 eyes (mean age, 72.8 years). Overall, the mean baseline IOP of 19.7 mmHg was reduced to 14.3 mmHg,14.0 mmHg, and 15.2 mmHg at 1, 2, and 3 years, respectively (). The average medicine use was reduced from 2.1 preoperatively to 0.4 at 12 months, and 0.5 and 0.6 at two and three years, respectively (). The frequency of surgical and postsurgical complications was low with no serious adverse events recorded. Conclusion. Canaloplasty was safe and effective in achieving long-term IOP reductions and reduced dependence on antiglaucoma medications. - 1 April 2016
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 25 (4) , e318-e323
Outcomes of Bleb Revision With Mitomycin C After Ex-PRESS Shunt Surgery
Investigate efficacy and safety of bleb revision using mitomycin C after Ex-PRESS shunt surgery. We performed chart reviews of 36 consecutive eyes from 34 patients with previous Ex-PRESS shunt surgery who underwent subsequent bleb revision with mitomycin C. The mean follow-up time was 13.5 months. The primary outcome measure was surgical success. Secondary outcomes included visual acuity, intraocular pressure, number of medications, and complications. Twenty-four eyes had open-angle glaucoma (61.1%). Mean time from Ex-PRESS to bleb revision was 8.8 months. Complete success rate for the immediate 3-month postoperative period was 94.4% and qualified success rate was 97.2%. Complete and qualified success rates for the entire follow-up period were 40% and 65.7%, respectively. Visual acuity remained stable throughout the study period, and at 1 year, average intraocular pressure was 14.7 mm Hg on an average of 1.7 medications. No major complications were reported. Bleb revision in eyes with an Ex-PRESS shunt is a safe and efficacious procedure. The surgical outcomes are within the range of published outcomes for bleb needling after trabeculectomy. Further research with larger sample size and longer follow-up is needed to confirm these results.
- 1 April 2016
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 25 (4) , e318-e323
Outcomes of Bleb Revision With Mitomycin C After Ex-PRESS Shunt Surgery
Investigate efficacy and safety of bleb revision using mitomycin C after Ex-PRESS shunt surgery. We performed chart reviews of 36 consecutive eyes from 34 patients with previous Ex-PRESS shunt surgery who underwent subsequent bleb revision with mitomycin C. The mean follow-up time was 13.5 months. The primary outcome measure was surgical success. Secondary outcomes included visual acuity, intraocular pressure, number of medications, and complications. Twenty-four eyes had open-angle glaucoma (61.1%). Mean time from Ex-PRESS to bleb revision was 8.8 months. Complete success rate for the immediate 3-month postoperative period was 94.4% and qualified success rate was 97.2%. Complete and qualified success rates for the entire follow-up period were 40% and 65.7%, respectively. Visual acuity remained stable throughout the study period, and at 1 year, average intraocular pressure was 14.7 mm Hg on an average of 1.7 medications. No major complications were reported. Bleb revision in eyes with an Ex-PRESS shunt is a safe and efficacious procedure. The surgical outcomes are within the range of published outcomes for bleb needling after trabeculectomy. Further research with larger sample size and longer follow-up is needed to confirm these results.
- 11 February 2016
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 44 (6) , 522-523
Efficacy of selective laser trabeculoplasty after canaloplasty
- 11 February 2016
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 44 (6) , 522-523
Efficacy of selective laser trabeculoplasty after canaloplasty